Overall, our results suggest that central obesity and MetS are associated with an impairment of HDL phospholipid metabolism and composition, which is partially driven by the lower activity of LCAT, with major changes correlating with the metabolic impairment of the patients. The gene discussed is LCAT; the disease is Abdominal obesity.